Current Landscape of Immunotherapy Trials Involving the Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Axis in Intrathoracic Tumors by Kareff, Samuel A., MD, MPH, Samtani, Suraj, MD, Burotto, Mauricio, MD, Prasad, Vinay, MD, MPH, Kim, Chul, MD, MPH

Get full text

Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised,... by Motzer, Robert J, Prof, Powles, Thomas, MD, Burotto, Mauricio, MD, Escudier, Bernard, MD, Bourlon, Maria T, MD, Shah, Amishi Y, MD, Suárez, Cristina, MD, Hamzaj, Alketa, MD, Porta, Camillo, MD, Hocking, Christopher M, MBBS, Kessler, Elizabeth R, MD, Gurney, Howard, MBBS, Tomita, Yoshihiko, Prof, Bedke, Jens, Prof, Zhang, Joshua, MD, Simsek, Burcin, PhD, Scheffold, Christian, MD, Apolo, Andrea B, MD, Choueiri, Toni K, Prof

Get full text